In a report released on August 11, Roanna Ruiz from Leerink Partners maintained a Hold rating on Enanta Pharmaceuticals, with a price target of $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Roanna Ruiz’s rating is based on a combination of factors related to Enanta Pharmaceuticals’ current financial and strategic position. The company reported revenues of $18.3 million for the third fiscal quarter of 2025, primarily from Mavyret royalties, and has completed enrollment for its RSVHR Phase 2 study, with results expected soon. This study is crucial as it could clarify the potential of zelicapavir in high-risk adults, which could impact future revenue streams.
Additionally, Enanta is advancing its immunology franchise, with ongoing studies and plans to introduce new programs in the near future. Despite these developments, the company’s cash reserves and projected royalty revenues are expected to sustain operations only until fiscal 2028, which may limit long-term growth potential. These factors, combined with the current price target of $7, suggest a balanced outlook, leading to the Hold rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.50 price target.